These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 232018)

  • 21. The impaired control of plasma renin activity in hypertensive patients with end-stage renal disease due to chronic glomerulonephritis.
    Yasuda G; Nagasawa T; Umemura S; Shionoiri H; Ishii M
    Clin Nephrol; 1994 Nov; 42(5):300-8. PubMed ID: 7851031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal vasodilatation caused by captopril in conscious normotensive and Goldblatt hypertensive dogs.
    Zimmerman BG; Mommsen C; Kraft E
    Proc Soc Exp Biol Med; 1980 Sep; 164(4):459-65. PubMed ID: 6997885
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of angiotensin I converting enzyme inhibitor (SQ 14225) on control of aldosterone.
    Eguchi T; Saito I; Nakamura R; Yasui T; Saruta T
    Acta Endocrinol (Copenh); 1980 Jun; 94(2):213-20. PubMed ID: 6251687
    [No Abstract]   [Full Text] [Related]  

  • 24. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension.
    Muiesan G; Alicandri CL; Agabiti-Rosei E; Fariello R; Beschi M; Boni E; Castellano M; Moniti E; Muiesan L; Romanelli G; Zanielli A
    Am J Cardiol; 1982 Apr; 49(6):1420-4. PubMed ID: 6280474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive effect of the oral angiotensin I-converting enzyme inhibitor in long-term treatment of hypertensive patients.
    Mizuno K; Gotoh M; Matsui J; Fukuchi S
    Jpn Heart J; 1981 Nov; 22(6):903-13. PubMed ID: 7040724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension.
    Matthews PG; McGrath BP; Johnston CI
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():135s-138s. PubMed ID: 232017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, aldosterone, and electrolyte responses.
    Baer L; Radichevich I; Williams GS
    J Cardiovasc Pharmacol; 1980; 2 Suppl 2():S206-16. PubMed ID: 6156357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response of chronic renovascular hypertension to surgical correction or prolonged blockade of the renin-angiotensin system by two inhibitors in the rat.
    Thurston H; Bing RF; Marks ES; Swales JD
    Clin Sci (Lond); 1980 Jan; 58(1):15-20. PubMed ID: 6986225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal artery stenosis with normal angiotensin II values. Relationship between angiotensin II and body sodium and potassium on correction of hypertension by captopril and subsequent surgery.
    Atkinson AB; Brown JJ; Davies DL; Leckie B; Lever AF; Morton JJ; Robertson JI
    Hypertension; 1981; 3(1):53-8. PubMed ID: 7009427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy of captopril in renovascular and essential hypertension.
    Case DB; Atlas SA; Marion RM; Laragh JH
    Am J Cardiol; 1982 Apr; 49(6):1440-6. PubMed ID: 6803561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.
    Atkinson AB; Morton JJ; Brown JJ; Davies DL; Fraser R; Kelly P; Leckie B; Lever AF; Robertson JI
    Br Heart J; 1980 Sep; 44(3):290-6. PubMed ID: 7000102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension.
    Ideishi M; Sasaguri M; Ikeda M; Arakawa K
    Clin Ther; 1989; 11(4):441-51. PubMed ID: 2550133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
    Atlas SA; Case DB; Yu ZY; Laragh JH
    Am J Med; 1984 Aug; 77(2A):13-7. PubMed ID: 6089554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Captopril in renovascular hypertension: long-term use in predicting surgical outcome.
    Atkinson AB; Brown JJ; Cumming AM; Fraser R; Lever AF; Leckie BJ; Morton JJ; Robertson JI
    Br Med J (Clin Res Ed); 1982 Mar; 284(6317):689-93. PubMed ID: 6802290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increase in plasma aldosterone during prolonged captopril treatment.
    Lijnen P; Staessen J; Fagard R; Amery A
    Am J Cardiol; 1982 Apr; 49(6):1561-3. PubMed ID: 7041598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Responsiveness to pressor agents in experimental renovascular and steroid hypertension. Effects of converting enzyme inhibitor and nephrectomy.
    Marks ES; Bing RF; Thurston H; Russell GI; Swales JD
    Hypertension; 1982; 4(2):238-44. PubMed ID: 6279494
    [No Abstract]   [Full Text] [Related]  

  • 38. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP; Karlberg BE; Nilsson OR; Wettre S
    Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril.
    Textor SC; Bravo EL; Fouad FM; Tarazi RC
    Am J Med; 1982 Nov; 73(5):719-25. PubMed ID: 6291388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
    Lechi A; Covi G; Capuzzo MG; Lechi C; Minuz P; Delva P; Scuro LA
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.